Relapsed/Refractory Lymphoma Clinical Trial
Official title:
A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
A phase II clinical study of tazemetostat combined with HMPL-689 in patients with R/R lymphoma. The study includes 2 phases: dose escalation phase (phase IIa) and expansion phase (phase IIb).
Dose Escalation Phase (Phase IIa ):Including 10-20 patients for dose escalation, the enrollment will continue until about 10 patients in the dose group with response, as to determine Recommended Phase II dose (RP2D). Dose Expansion Phase (Phase IIb):Multiple expansion cohorts will be set up according to different tumor types, and about 15-20 patients will be enrolled in each cohort to further observe the anti-tumor effect of Tazemetostat combined with HMPL-689 in different pathological types of R/R lymphoma. This study is expected to enroll 85-140 patients total in Phase IIa and phase IIb. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02259010 -
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
|
Phase 1 | |
| Not yet recruiting |
NCT05293028 -
Study of F527 in Patients With Relapsed or Refractory Lymphoma
|
Phase 1 | |
| Recruiting |
NCT05400876 -
To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05189093 -
Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT05271279 -
A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors
|
Early Phase 1 | |
| Completed |
NCT02214147 -
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
|
Phase 1 |